

- Howard OM. Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3+CD4+CD25+ T regulatory cell *in vivo* and enhances their capacity to suppress EAE. *Eur J Immunol* 2006; **36**:2139–49.
- 74 Hamdi H, Godot V, Maillot MC *et al.* Induction of antigen-specific regulatory T lymphocytes by human dendritic cell expressing glucocorticoid-induced leucine zipper. *Blood* 2007; **110**:211–19.
 - 75 Benninger MS, Ahmad N, Marple BF. The safety of intranasal steroids. *Otolaryngol Head Neck Surg* 2003; **129**:739–50.
 - 76 Allen DB, Melzer EO, Lemanske RF Jr *et al.* No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. *Allergy Asthma Proc* 2002; **23**:407–13.
 - 77 Schenkel EJ, Skoner DP, Bronsky EA *et al.* Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. *Periatrics* 2000; **105**:e22.
 - 78 Daley-Yates PT, Kunka RL, Yin Y, Andrews SM, Callejas S, Ng C. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. *Eur J Clin Pharmacol* 2004; **60**:265–8.
 - 79 Okubo K, Nakashima M, Miyake N, Komatsubara M, Okuda M. Comparison of fluticasone furoate and fluticasone propionate for the treatment of Japanese cedar pollinosis. *Allergy Asthma Proc* 2009; **30**:84–94.
 - 80 Arikan OK, Koc C, Kendi T, Muluk NB, Ekici A. CT assessment of the effect of fluticasone propionate aqueous nasal spray treatment on lower turbinate hypertrophy due to vasomotor rhinitis. *Acta Otolaryngol* 2006; **126**:37–42.
 - 81 Brooks CD, Karl KJ, Francom SF. Oral methylprednisolone acetate (Medrol tablets) for seasonal allergic rhinitis: examination of dose and symptom response. *J Clin Pharmacol* 1993; **33**:816–22.
 - 82 Vargas R, Dockhorn RJ, Findlay SR, Korenblat PE, Field EA, Kral KM. Effect of fluticasone propionate aqueous nasal spray versus oral prednisone on the hypothalamic–pituitary–adrenal axis. *J Allergy Clin Immunol* 1998; **102**:191–7.
 - 83 Mygind N, Laursen LC, Dahl M. Systemic corticosteroid treatment for seasonal allergic rhinitis: a common but poorly documented therapy. *Allergy* 2000; **55**:11–15.
 - 84 Nasser SMS, Ewan PW. Depot corticosteroid treatment for hay fever causing avascular necrosis of both hips. *BMJ* 2001; **322**:1589–91.
 - 85 Bernstein DI, Levy AI, Hampel FC *et al.* Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. *Clin Exp Allergy* 2004; **34**:952–7.
 - 86 Fokkens WJ, Jogi R, Reinartz S *et al.* Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen. *Allergy* 2007; **62**:1078–84.
 - 87 Kaiser HB, Naclerio RM, Given J *et al.* Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. *J Allergy Clin Immunol* 2007; **119**:1430–7.
 - 88 Baroody FM, Foster KA, Markaryan A, deTineo M, Naclerio RM. Nasal ocular reflexes and eye symptoms in patients with allergic rhinitis. *Ann Allergy Asthma Immunol* 2008; **100**:194–9.
 - 89 Kremer B, den Hartog IIM, Jolles J. Relationship between allergic rhinitis, disturber cognitive functions and psychological wellbeing. *Clin Exp Allergy* 2002; **32**:1310–15.
 - 90 Walker S, Khan-Wasti S, Fletcher M *et al.* Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case–control study. *J Allergy Clin Immunol* 2007; **120**:381–7.
 - 91 Young T, Finn L, Kim H. Nasal obstruction as a risk factor for sleep-disordered breathing. The University of Wilcoxon Sleep and Respiratory Research Group. *J Allergy Clin Immunol* 1997; **99**:S757–62.
 - 92 Vuorman EPF, van Veggel IMA, Uiterwijk MMC *et al.* Seasonal allergic rhinitis and anti-histamine effect on children's learning. *Ann Allergy* 1993; **71**:121–6.
 - 93 Craig TJ, Hanks CD, Fisher LH. How do topical nasal corticoids improve sleep and daytime somnolence in allergic rhinitis? *J Allergy Clin Immunol* 2005; **116**:1264–6.
 - 94 Mansfield LE, Posey CR. Daytime sleepiness and cognitive performance improve in seasonal allergic rhinitis treated with intranasal fluticasone propionate. *Allergy Asthma Proc* 2007; **28**:226–9.
 - 95 Kawauchi H. Medication for allergic rhinitis. *Otolaryngol Head Neck Surg* 2004; **76**:39–44.
 - 96 Graft D, Aaronson D, Chervinsky P *et al.* A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray. *J Allergy Clin Immunol* 1996; **98**:724–31.
 - 97 Yokoo E. Prophylactic treatment of Japanese cedar pollinosis with intranasal corticosteroids. *Prog Med* 2005; **25**:3195–9.
 - 98 Okubo K, Nagakura T, Usui II *et al.* Evaluation of efficacy, safety and effects on rhinitis-specific QOL by fluticasone propionate in pediatric patients with seasonal allergic rhinitis. *Allergol Immunol* 2005; **12**:318–31.
 - 99 Adcock IM, Ito K, Barnes PJ. Glucocorticoids: effects on gene transcription. *Proc Am Thorac Soc* 2004; **1**:247–54.

CRTH2 Plays an Essential Role in the Pathophysiology of Cry j 1-Induced Pollinosis in Mice¹

Rie Nomiya,* Mitsuhiro Okano,* Tazuko Fujiwara,* Megumi Maeda,[†] Yoshinobu Kimura,[†] Kosuke Kino,[‡] Minehiko Yokoyama,[‡] Hiroyuki Hirai,[§] Kinya Nagata,[§] Toshifumi Hara,^{||} Kazunori Nishizaki,* and Masataka Nakamura^{2||}

PGD₂ is the major prostanoid produced during the acute phase of allergic reactions. Two PGD₂ receptors have been isolated, DP and CRTH2 (chemoattractant receptor-homologous molecule expressed on Th2 cells), but whether they participate in the pathophysiology of allergic diseases remains unclear. We investigated the role of CRTH2 in the initiation of allergic rhinitis in mice. First, we developed a novel murine model of pollinosis, a type of seasonal allergic rhinitis. Additionally, pathophysiological differences in the pollinosis were compared between wild-type and CRTH2 gene-deficient mice. An effect of treatment with ramatroban, a CRTH2/TP-prostanoid receptor dual antagonist, was also determined. Repeated intranasal sensitization with Cry j 1, the major allergen of *Cryptomeria japonica* pollen, in the absence of adjuvants significantly exacerbated nasal hyperresponsive symptoms, Cry j 1-specific IgE and IgG1 production, nasal eosinophilia, and Cry j 1-induced in vitro production of IL-4 and IL-5 by submandibular lymph node cells. Additionally, CRTH2 mRNA in nasal mucosa was significantly elevated in Cry j 1-sensitized mice. Following repeated intranasal sensitization with Cry j 1, CRTH2 gene-deficient mice had significantly weaker Cry j 1-specific IgE/IgG1 production, nasal eosinophilia, and IL-4 production by submandibular lymph node cells than did wild-type mice. Similar results were found in mice treated with ramatroban. These results suggest that the PGD₂-CRTH2 interaction is elevated following sensitization and plays a proinflammatory role in the pathophysiology of allergic rhinitis, especially pollinosis in mice. *The Journal of Immunology*, 2008, 180: 5680–5688.

Pollinosis, a type of seasonal allergic rhinitis, is the most common allergic respiratory disease and is a global health problem that is increasing in prevalence (1–3). For example, as much as 10–20% of the Japanese population suffers from Japanese cedar pollinosis (JCP).³

Intensive and extensive studies on pollinosis have greatly improved the understanding of its etiology and pathology (4). Mouse models of allergic rhinitis have contributed to these advances. However, these mouse models usually use adjuvants and/or strong Ags to efficiently sensitize animals (5–9). To further examine the pathophysiological mechanism underlying pollinosis, a murine model that naturally mimics human pollinosis by intranasal ad-

ministration of pollen extracts in the absence of adjuvants is needed.

Prostanoids are thought to participate in allergic inflammation (10). PGD₂ is one of the most important of these and it plays roles in allergic respiratory diseases including allergic rhinitis (10–15). For example, nebulized PGD₂ enhances Th2-type inflammatory responses and eosinophilia, leading to the development of airway hyperresponsiveness (14). PGD₂ acts via the D-prostanoid receptor (DP) and chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) (16). The expression patterns and signaling pathways utilized by DP and CRTH2 are different, suggesting that they have distinct roles in allergic responses (16, 17). It appears that signals via DP promote eosinophil survival, whereas signals via CRTH2 mediate shape changes, chemotaxis, and degranulation by eosinophils (16, 18, 19).

The role of CRTH2 in allergic airway inflammation in vivo remains controversial (17). CRTH2 has been found to participate in the recruitment of eosinophils from the bone marrow into the bloodstream (19, 20), in eosinophilic airway inflammation (11), and in airway eosinophilia and hyperresponsiveness (21), suggesting that it plays a proinflammatory role in vivo. On the other hand, mice deficient for CRTH2 (CRTH2^{-/-}) show eosinophil recruitment and IL-5 production by splenocytes in an asthma model, suggesting that CRTH2 mediates antiinflammatory signals (22). In human nasal mucosa, CRTH2 is expressed in eosinophils and a subset of T cells (23). We have recently reported that there is a close correlation between the number of eosinophils infiltrating into nasal mucosa and the amount of CRTH2, but not DP, in nasal mucosa (12). Also, CRTH2^{-/-} mice have been found to show reduced eosinophil infiltration into skin in a model of chronic allergic skin inflammation (24).

In this study, we established a novel murine model of pollinosis and used it to determine the pathophysiological role of CRTH2 in

*Department of Otolaryngology–Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;

[†]Division of Biomolecular Science, The Graduate School of Natural Science and Technology, Okayama University, Okayama, Japan; [‡]Meiji Company, Odawara, Japan; [§]Department of Advanced Medicine and Development, BioMedical Laboratories, Saitama, Japan; and ^{||}Human Gene Sciences Center, Tokyo Medical and Dental University, Tokyo, Japan

Received for publication July 23, 2007. Accepted for publication February 8, 2008.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science, and Technology, Japan (14704143), and Research on Allergic Disease and Immunology of the Ministry of Health, Labor, and Welfare, Japan (14210301).

² Address correspondence and reprint requests to Dr. Mitsuhiro Okano, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikatacho, 700-8558 Okayama, Japan. E-mail address: mokano@cc.okayama-u.ac.jp

³ Abbreviations used in this paper: JCP, Japanese cedar pollinosis; CRTH2, chemoattractant receptor-homologous molecule expressed on Th2 cells; DP, D-prostanoid receptor; TP, T-prostanoid receptor; WT, wild type.

Copyright © 2008 by The American Association of Immunologists, Inc. 0022-1767/08/52.00




FIGURE 1. Experimental design used to investigate the effect of nasal exposure to Cry j 1 in mice. BALB/c mice (6–9 per group) were sensitized by intranasal administration of either 1.0 or 5.0 µg of Cry j 1 in 10 µl PBS in the absence of adjuvants once a week for 3 wk (on days 1, 8, and 15). One week after the third sensitization, mice were challenged by intranasal administration of one fifth Cry j 1, respectively every day for 7 consecutive days (on days 22 to 27). As a control, mice were treated with PBS, except for the final challenge, where mice were treated with 1.0 µg of Cry j 1. Immediately after the final nasal challenge, nasal symptoms were observed for 10 min, and 16 h after the final nasal challenge, peripheral blood was collected, and the specific Ab content in the serum was measured. After the blood sampling, mice were sacrificed, and the nose and submandibular lymph nodes were obtained for further analysis.

the disease. In this model, intranasal sensitization with Cry j 1, the major allergen of *Cryptomeria japonica* pollen, in the absence of adjuvant induced allergic rhinitis closely resembling human pollinosis. We found that a lack of CRTH2 in the mutant mice greatly reduces allergic pathophysiology in this model.

Materials and Methods

Animals and Ages

BALB/c mice were purchased from Charles River Laboratories Japan and CLEA Japan. Homozygous CRTH2-deficient and wild-type BALB/c mice were obtained as described previously (24). Female mice (7–11 wk old) were used in all the experiments. The mice were maintained in specific pathogen-free conditions at Okayama University and Tokyo Medical and Dental University in accordance with the guidelines set forth by the university committees. All experimental protocols and procedures in the present study were approved by the University Animal Care and Use Committees. Cry j 1 was purified from crude extracts of *C. japonica* pollen as described previously (25). Endotoxin contamination was considered to be negligible due to a negative result in the Endospec ES test (Seikagaku). Ramatroban was obtained from Bayer Yakuhin. Protein concentrations were determined using a bicinchoninic acid assay (Pierce) according to the manufacturer's instructions.

Sensitization of mice

Mice (6–9 animals per group) were sensitized by intranasal application of serial doses of Cry j 1 in 10 µl PBS in the absence of adjuvants using a microsyringe (Hamilton Medical). The low-dose sensitization consisted of a series of administrations of 1.0 µg of Ag once a week for 3 wk (on days 1, 8, and 15), followed by administration of 0.2 µg Ag every day for 7 consecutive days (on days 22 to 28). For high-dose sensitization, 5.0 and 1.0 µg of Cry j 1 were administered once a week for 3 wk (on days 1, 8, and 15) and every day for 7 consecutive days (on days 22 to 28), respectively. As a control, mice were treated with PBS instead of the Ag at all points except for the final challenge, where the mice were administered 1.0 µg of Cry j 1 (Fig. 1). Immediately after the final nasal challenge, the frequencies of sneezing and nasal rubbing were counted in a blinded manner for 10 min. Peripheral blood was collected from the tail vein 16 h after the final nasal challenge, and then sera were prepared by centrifugation at 200 × g, and the levels of Cry j 1-specific Ab in the serum were determined by ELISA. The mice were then sacrificed, and the nose and submandibular lymph nodes were isolated for further immunological and histological analyses.

To determine whether the effect of CRTH2 deficiency is at the level of sensitization or amplification of allergic cascade, outcomes of pollinosis were compared with CRTH2^{-/-} mice sensitized and subsequently challenged with Cry j 1 and nonsensitized CRTH2^{-/-} mice with a single challenge with Cry j 1.

Ramatroban treatment

Ramatroban was suspended in 5% methyl cellulose and administered orally at a dose of 30 mg/kg body weight once a day from 1 day before the first sensitization to the final challenge (day 0 to day 28). Control mice were given 5% methyl cellulose alone.

Ab determination

The levels of Cry j 1-specific IgE, IgG1, and IgG2a were determined by ELISA as previously described (26). The levels of Cry j 1-specific IgE were measured using biotinylated Cry j 1 (Hayashibara Biochemical Laboratories) as a detecting reagent. The titers of Ag-specific Abs were estimated according to the mean OD at 450 nm of serum dilutions of 1/20 for IgE and 1/100 for IgG1 and IgG2a.

In vitro culture of submandibular lymph node cells and measurement of cytokine production

Submandibular lymph nodes from mice were dispersed and filtered through a 70-µm cell strainer (BD Biosciences) to yield a single-cell suspension. Lymph node cells were suspended in RPMI 1640 supplemented with 10% heat-inactivated FCS (Invitrogen), 100 µg/ml streptomycin, 100 U/ml penicillin, and 20 mM L-glutamine (Sigma-Aldrich). Cells (4×10^5 cells/200 µl) were cultured in the presence or absence of 10 µg/ml Cry j 1 in 96-well flat-bottom plates (BD Biosciences) at 37°C in humidified atmosphere of 5% CO₂ and 95% air. After 72 h of culture, supernatants were harvested. The levels of IL-4, IL-5, and IFN-γ in the culture supernatant were measured using OptEIA sets (BD Biosciences). The levels of IL-13 were measured using DuoSet ELISA development kit (R&D Systems). The detection limits for IL-4, IL-5, IL-13, and IFN-γ in this system were 10, 30, 40, and 60 pg/ml, respectively.

Histological examination

Histological examination was performed as previously described (26). Coronal nasal sections were stained with H&E and Luna solution to detect mononuclear cells and eosinophils, respectively. A blind test was conducted to determine the numbers of infiltrating cells in the posterior part of nasal septum using a high-power (10 × 40) microscopic field.

To determine the infiltration of T cells into nasal mucosa, immunohistochemistry for CD3 was examined. Paraffin-embedded nasal tissues were sectioned into 5-µm slices, deparaffinized, rehydrated and retrieved with microwave. Endogenous peroxidase activity was quenched with 3% H₂O₂, and nonspecific protein binding was blocked with normal rabbit serum (DAKO Japan) for 60 min. After this, the tissue sections were incubated with goat anti-mouse CD3-ε polyclonal Ab (sc-1127; Santa Cruz Biotechnology) or control goat IgG Ab (M-20; Santa Cruz Biotechnology) overnight at 4°C. To detect the reaction, N-Histofine Simple Stain MAX PO (G) (Nichirei Biosciences) and diaminobenzidine substrate (DAKO Japan) was used according to the manufacturers' instructions.

Real-time quantitative PCR in nasal mucosa

Mucosal tissues were removed from nasal septum 16 h following the final nasal challenge, immediately soaked in buffer containing guanidine isothiocyanate from the RNeasy Mini Kit (Qiagen), and stored at -80°C until use. Extraction of total cellular RNA, reverse transcription to generate cDNA, and real-time quantitative PCR were performed using a Chromo4 Real-Time PCR detector (Bio-Rad Laboratories, Hercules) and QuantiTect SYBR Green PCR reagents (Qiagen) as described previously (12). The primer sequences for CRTH2 and GAPDH are shown in Table I. Standard curves for both CRTH2 and GAPDH were generated using a PCR fragment of CRTH2 and plasmid DNA of GAPDH as a standard, respectively. Then absolute copy number of CRTH2 and GAPDH for each sample was calculated, and samples were reported with a CRTH2 copy number relative to GAPDH.

Relative amounts of IL-4, IL-5, IL-13, IFN-γ, IL-1β, IL-6, TNF-α, RANTES, and eotaxin mRNA in nasal mucosa were also measured. The primers used are listed in Table I.

Statistical analysis

Statistical significance was determined by nonparametrical Mann-Whitney U tests. *p* values of <0.05 were considered to indicate statistical significance. Values are shown as means ± SEM.

Table I. Primary sequences used for real-time PCR amplifications

	Forward Primer	Reverse Primer	Amplification Size (bp)	Genbank Accession No.
IL-4	CCTCAGCAACGAAGAACA	CTGCAGCTCCATGAGAACAC	133	NM_021283
IL-5	TCAGCTGTGTCTGGGCCACT	TTATGAGTAGGGACAGGAAGCCTCA	133	NM_010558
IL-13	TGCTTGCCCTGGTGGTCTC	CAGGTCCACACTCCATACC	151	NM_008355
IFN- γ	GCGTCATTGAATCACACCTG	ACCTGTGGGTGTGACCTC	103	NM_008337
IL-1 β	TCCAGGATGAGGACATGAGCAC	GAACGTACACACAGCAGGTTA	105	NM_008361
IL-6	CCACTTCACAAGTCGGAGGCTTA	GCAAGTGCATCATCGTTGTTTCATAC	112	NM_031168
TNF- α	ATGAGCACAGAAAGCATGATC	TCCACTTGGTGGTTTGCTACG	305	NM_013693
RANTES	AGATCTCTGCAGCTGCCCTCA	GGAGCACTTGCTGCTGGTGTAG	170	NM_013653
Eotaxin	CAGATGCACCTGAAAGCCATA	TGCTTTGTGGCATCCTGGAC	96	NM_011330
CRTH2	TCTCAACCAATCAGCACACC	CCTCAAGAGTGGACAGAGC	173	NM_009962
GAPDH	ACCACAGTCCATGCCATCAC	TCCACCACCTGTTGCTGTA	452	NM_008084

Results

Induction of nasal symptoms in Cry j 1-sensitized mice

We first attempted to generate a mouse model mimicking human allergic rhinitis, especially pollinosis, which causes symptoms of nasal symptoms, including sneezing and nasal rubbing, by intranasal administration of Cry j 1. We found a significant and dose-dependent increase in the frequency of sneezing in BALB/c mice sensitized with Cry j 1. Mice that were treated with PBS alone sneezed 1.8 ± 0.3 (mean \pm SEM) times in the 10 min following the final Ag administration, whereas they sneezed 5.8 ± 1.2 times and 15.7 ± 2.7 times when treated with low and high doses of Ag, respectively (Fig. 2A). Similarly, immediately after the final Ag challenge, nasal rubbing was observed more frequently in mice sensitized with a high dose of Cry j 1 than in control mice (37.3 ± 5.8 vs 11.2 ± 2.7 times in 10 min). At a low dose of Cry j 1, there was no significant increase in the frequency of nasal rubbing (Fig. 2B).

Development of Th2-type immune responses in Cry j 1-sensitized mice


To further characterize the pathogenesis of immune responses caused by Cry j 1, we monitored several parameters associated with pollinosis. Nasal challenge with a low or high dose of Cry j

1 caused a considerable increase in the concentration of Cry j 1-specific IgE in sera when measured 1 day after the final challenge (Fig. 2C). There was also a significant elevation in the concentration of Cry j 1-specific IgG1 (Fig. 2D). The concentration of Cry j 1-specific IgE and IgG1 was not appreciably different at the low and high doses of Cry j 1. Cry j 1, however, had little effect on the level of Cry j 1-specific IgG2a (Fig. 2E).

Eosinophil infiltration into nasal mucosa, another characteristic of pollinosis, is rarely seen in the nasal mucosa in control mice (Fig. 3A). On the contrary, there was a marked accumulation of eosinophils not only in the lamina propria but also in the epithelial layer in mice 1 day after the final challenge (Fig. 3, B and C). Eosinophil numbers per field following intranasal Cry j 1 sensitization/challenge at both low and high doses were significantly higher than in control mice (Fig. 3D). The nasal mucosa of Cry j 1-sensitized mice also showed severe infiltration by mononuclear cells. The nasal septum of mice treated with low and high doses of Cry j 1 contained more mononuclear cells per field (59.8 ± 9.0 ($p = 0.055$) and 80.2 ± 9.1 ($p = 0.016$), respectively) than did control mice (39.8 ± 4.7).

We next examined the in vitro production of cytokines in culture by cells isolated from submandibular lymph nodes from mice treated in vivo with or without Cry j 1. The amounts of IL-4 and

FIGURE 2. Nasal hyperresponsive symptoms and Ab production in mice following intranasal sensitization and challenge with Cry j 1. Mice were sensitized and challenged by intranasal administration of Cry j 1. Nasal allergic symptoms, including the frequency of sneezing (A) and rubbing (B), were determined for the 10 min immediately following the final nasal challenge (day 28). Mean frequencies \pm SEM are shown. Serum samples were obtained 16 h after the final intranasal challenge. Cry j 1-specific IgE (C), IgG1 (D), and IgG2a (E) levels were determined by ELISA. Mean OD values \pm SEM are shown. Results are representative of two independent experiments.






FIGURE 3. Nasal eosinophilia and cytokine production by submandibular lymph node cells following intranasal sensitization and challenge with Cry j 1. Mice were sensitized and challenged by intranasal administration of PBS (A), low-dose Cry j 1 (B), or high-dose Cry j 1 (C) according to the schedule shown in Fig. 1. Sixteen hours after the final challenge, nasal sections were collected, fixed, and decalcified, and eosinophils in the nasal mucosa were detected by Luna stain. D, The numbers of eosinophils in the posterior portion of the nasal septum were determined per high-power (10×40) microscopic field. Mean numbers of infiltrating cells per field \pm SEM are shown. Sixteen hours after the final challenge, submandibular lymph node cells were isolated and cultured in the absence or presence of Cry j 1 for 72 h. IL-4 (E), IL-5 (F), and IFN- γ (G) were measured by ELISA. Mean concentrations \pm SEM are shown. Results are representative of two independent experiments.

IL-5 produced by the cells were in proportion to the doses used for in vivo sensitization (Fig. 3, E and F). IFN- γ production was slightly enhanced in lymph node cells from mice treated with a high dose of Cry j 1 compared with control mice, but the increase was not statistically significant (Fig. 3G).

CRTH2 mRNA expression in nasal mucosa of Cry j 1-sensitized mice

We next measured the expression of CRTH2 at sites of nasal inflammation. Control mice treated with PBS expressed a low level of CRTH2 mRNA in the mucosal tissue of the nasal septum. In mice treated with Cry j 1, the level of CRTH2 mRNA was significantly increased (Fig. 4). Thus, we further investigated whether CRTH2 is positively or negatively involved in the pathophysiology of pollinosis using CRTH2 $^{-/-}$ mice.

Impaired pathophysiology of pollinosis in Cry j 1-sensitized CRTH2 $^{-/-}$ mice

A high dose of Cry j 1 was administered to both wild-type (WT) and CRTH2 $^{-/-}$ mice, and the nasal hyperresponsive symptoms were examined immediately after the final nasal challenge. Notably, the number of sneezes in 10 min by the Cry j 1-sensitized mutant mice was significantly lower than by the WT mice (Fig. 5A). Nasal rubbing was also significantly lower in the CRTH2 $^{-/-}$ mice than in the WT mice (Fig. 5B).

The level of Cry j 1-specific IgE in serum samples collected on the day following the final Ag challenge was significantly lower for mutant mice than for WT mice (Fig. 5C). Production of Cry j 1-specific IgG1 was similarly reduced in CRTH2 $^{-/-}$ mice compared with WT mice (Fig. 5D). In contrast, serum levels of Cry j 1-specific IgG2a were the same in the two mouse strains (Fig. 5E).

The number of eosinophils infiltrating into the nasal septum following administration of Cry j 1 was also significantly lower in the CRTH2 $^{-/-}$ mice than in the WT mice (Fig. 6A–C). Although the number of mononuclear cells infiltrating the nasal septum was not significantly different in the mutant and WT mice (Fig. 6D), the number of infiltrating CD3 $^{+}$ cells was significantly reduced in CRTH2 $^{-/-}$ mice as compared with WT mice (Fig. 6E). These





FIGURE 4. Relative amounts of CRTH2 mRNA in nasal mucosa. Mice (6 per group) were sensitized by intranasal administration of 5.0 μ g of Cry j 1 once a week for 3 wk. One week after the third sensitization, mice were challenged by intranasal administration of 1.0 μ g of Cry j 1 each day for 7 consecutive days. Control animals were treated with PBS at all steps except for the final challenge, where they were treated with 1.0 μ g of Cry j 1. Sixteen hours after the final challenge with Cry j 1, mucosal tissues were removed from the nasal septum. The CRTH2 mRNA levels were estimated using real-time quantitative PCR. Results are the mean amounts of mRNA \pm SEM.

FIGURE 5. Nasal symptoms and Ab production in WT and CRTH2^{-/-} mice following the final nasal challenge with Cry j 1. Mice were sensitized and challenged by intranasal administration of Cry j 1. Sneezing (A) and rubbing (B) frequency were measured for 10 min following the final nasal challenge (day 28). Mean frequencies \pm SEM are shown. Sixteen hours after the final nasal challenge, blood was sampled from mice, and levels of serum Cry j 1-specific IgE (C), IgG1 (D), and IgG2a (E) were determined by ELISA. Mean ODs \pm SEM are shown. Results are representative of two independent experiments.



results suggest that CRTH2 deficiency affects infiltration of not only eosinophils but also T cells.

To clarify the link between CRTH2 deficiency and the relief of allergic symptoms, we further investigated cytokine production in vitro by cells from submandibular lymph nodes obtained the day after the final Ag challenge. The amount of IL-4 was 5-fold lower in CRTH2^{-/-} mice than in WT mice (Fig. 6F). Additionally, there was a slight reduction in the amount of IL-5 (Fig. 6G) and a slight

increase in the amount of INF- γ (Fig. 6I) in the cells from CRTH2^{-/-} mice, but the differences were not significant. On the contrary, the levels of IL-13 were significantly higher in CRTH2^{-/-} mice as compared with WT mice (Fig. 6H).

Additionally, mRNA levels of Th2 cytokines (IL-4, IL-5, and IL-13), Th1 cytokine (INF- γ), proinflammatory cytokines (IL-1 β , IL-6 and TNF- α), and eosinophil-chemotactic chemokines (RANTES and eotaxin) in nasal mucosa were determined. The





FIGURE 6. Histological changes and cytokine production by submandibular lymphocytes following nasal challenge with Cry j 1 in WT and CRTH2^{-/-} mice. WT (A) and CRTH2^{-/-} (B) mice were sensitized and challenged by intranasal administration of Cry j 1. Sixteen hours following the final nasal challenge with Cry j 1, nasal sections were collected, fixed, and decalcified, and eosinophils in nasal mucosa were detected by Luna stain. C. The number of eosinophils in the posterior portion of the nasal septum was determined per high-power (10 \times 40) microscopic field. Mean numbers of infiltrating eosinophils per field \pm SEM are shown. Numbers of mononuclear cells (D) and CD3⁺ cell (E) in the nasal septum were also determined. Sixteen hours after the final challenge with Cry j 1, submandibular lymph node cells were isolated and cultured with Cry j 1 for 72 h. IL-4 (F), IL-5 (G), IL-13 (H), and INF- γ (I) were measured by ELISA. Mean concentrations \pm SEM are shown. Results are representative of two independent experiments.

FIGURE 7. Relative amounts of cytokines/chemokines mRNA in nasal mucosa following nasal challenge with Cry j 1 in WT and CRTH2^{-/-} mice. Sixteen hours after the final nasal challenge with Cry j 1, mucosal tissues were removed from nasal septum. Relative amounts of IL-4 (A), IL-5 (B), IL-13 (C), IFN- γ (D), IL-1 β (E), IL-6 (F), TNF- α (G), RANTES (H), and eotaxin (I) mRNA were compared between WT and CRTH2^{-/-} mice. Results are the mean amounts of mRNA \pm SEM.



levels of IL-4 and IL-5 mRNA were significantly lower in CRTH2^{-/-} mice as compared with WT mice, whereas the levels of other cytokines/chemokines were similar between CRTH2^{-/-}

and WT mice (Fig. 7). These results suggest that reduced nasal eosinophilia in CRTH2 deficiency is associated with reduced levels of IL-5 but not RANTES or eotaxin in this model. Additionally,




FIGURE 8. Effects of ramatroban on murine JCP. Ramatroban (30 mg/kg body weight), suspended in 5% methyl cellulose, was given orally once a day from 1 day before the first sensitization to the final challenge (day 0 to day 28). Control mice were given 5% methyl cellulose alone. After the final intranasal challenge, the frequencies of sneezing (A) and rubbing (B) were counted, and serum levels of Cry j 1-specific IgE (C), IgG1 (D), IgG2a (E), and nasal eosinophil count (F), as well as Cry j 1-induced IL-4 (G), IL-5 (H) and IFN- γ (I) were determined as described in *Materials and Methods*. Results are expressed as means \pm SEM.

it is suggested that CRTH2-mediated pathway may induce pathology without regulating local production of these proinflammatory cytokines.

Outcomes of pollinosis were compared between sensitized/challenged CRTH2^{-/-} mice and nonsensitized/single-challenged CRTH2^{-/-} mice. The levels of Cry j 1-specific IgE (0.159 ± 0.044 vs 0 ± 0 OD at 450 nm; $p = 0.003$), Cry j 1-specific IgG1 (0.638 ± 0.163 vs 0 ± 0 OD at 450 nm; $p = 0.004$), nasal eosinophilia (66.4 ± 8.2 vs 6.6 ± 1.1 cells/field; $p = 0.005$), and IL-4 production by submandibular lymph node cell (72.8 ± 31.1 vs 6.7 ± 3.8 pg/ml; $p = 0.004$) were significantly higher in sensitized and subsequently challenged CRTH2^{-/-} mice as compared with nonsensitized and single-challenged CRTH2^{-/-} mice. However, the frequencies of sneezing (1.7 ± 0.5 vs 0.6 ± 0.2 times in 10 min; $p = 0.088$) and rubbing (12.3 ± 2.6 vs 10.2 ± 3.1 times in 10 min; $p = 0.516$) were similar between two groups, suggesting that CRTH2 is particularly essential for the development of nasal symptoms.

Effect of ramatroban on Cry j 1-induced pollinosis

As seen in CRTH2-deficient mice, treatment with ramatroban significantly reduced several indicators of pollinosis including sneezing, Cry j 1-specific IgG1 production, and Cry j 1-induced IL-4 production by submandibular lymph node cells as compared with the control treatment (Fig. 8, A, D, and G). Although the differences did not reach to the statistical level, other parameters such as nasal rubbing, Cry j 1-specific IgE production, nasal eosinophilia, and Cry j 1-induced IL-5 production were also reduced by the treatment with ramatroban (Fig. 8, B, C, F, and H).

Discussion

In the present study, we analyzed the pathophysiological effects of nasal exposure to Cry j 1 in BALB/c mice. Mice sensitized with Cry j 1 without adjuvants showed not only allergic symptoms such as sneezing and rubbing but also produced Cry j 1-specific IgE and IgG1 and displayed nasal eosinophilia. Additionally, submandibular lymph node cells isolated from these mice produced IL-4 and IL-5 in recall response to Cry j 1. These results suggest that intranasal sensitization with Cry j 1 induces pollinosis in BALB/c mice.

To investigate the initiation of allergic rhinitis in vivo, administration of Ags via the natural route (i.e., through the nostril) is desirable. In fact, it is known that administration of Ags through different routes results in different degrees of IgE production (27, 28). Also, murine models of allergic rhinitis have been generated by intranasal or aerosol-mediated sensitization (8, 29), but these models generally employ adjuvants such as cholera toxin, which have immunoregulatory effects that may distort the physical sensitization (30, 31). Therefore, we and others have established murine models of allergic rhinitis by intranasal sensitization with Ags including *Schistosoma mansoni* egg Ag, phospholipase A₂ from honeybee venom, extracts of *Aspergillus fumigatus*, OVA, and trimellitic anhydride in the absence of adjuvants (5–7, 9, 32). We think that our current model is the first in which murine pollinosis was induced by intranasal sensitization with pollen allergen in the absence of an adjuvant. This model may be useful not only for understanding the pathophysiology of pollinosis but also for developing and/or testing new therapies for allergic rhinitis, especially JCP.

BALB/c mice sensitized with Cry j 1 showed an increase in the expression of CRTH2 mRNA in the nasal septum compared with control mice. This agrees with our recent report demonstrating that the amount of CRTH2 mRNA in nasal mucosa is significantly higher in patients with allergic rhinitis than in control subjects not

showing hypertrophy of inferior turbinates (12). These results suggest that the expression of CRTH2 may play a role in the pathogenesis of allergic rhinitis both in humans and in mice. In fact, it is known that the expression of CRTH2 in eosinophils and CD4⁺ T cells is elevated in atopic patients (33–35). CRTH2 is expressed by eosinophils and a subset of CD3⁺ T cells in nasal mucosa, especially in patients with allergic rhinitis (23). Because a mAb against murine CRTH2 that can be used for immunohistochemistry is not currently available, we could not investigate the phenotype of cells expressing CRTH2 in mice.

The pathophysiology of allergic rhinitis was clearly impaired in CRTH2^{-/-} mice. Following repeated intranasal sensitization and nasal challenge with Cry j 1, CRTH2^{-/-} mice displayed reduced nasal symptoms, production of Cry j 1-specific IgE and IgG1, and nasal eosinophilia compared with WT mice. Additionally, submandibular lymph node cells from Cry j 1-sensitized CRTH2^{-/-} mice produced significantly less IL-4 and IL-5 in response to Cry j 1 than those from WT mice. We think that the present results are the first demonstration of the in vivo role of CRTH2 in the initiation of Th2 responses in the upper airway.

We also found that Cry j 1-specific IgE and IgG1 but not IgG2a production was impaired in CRTH2^{-/-} mice. Ag-specific IgE/IgG1 and IgG2a production is known to be positively regulated by Th2 and Th1 responses, respectively, in mice (36). Thus, our results indicate that signals mediated by CRTH2 selectively enhance Th2-type Ab production. The decreased production of IL-4 by submandibular lymph node cells from CRTH2^{-/-} mice in response to Cry j 1 restimulation supports this result because IL-4 plays a critical role in IgE synthesis in vivo (37). Although whether CRTH2 activation directly leads to IL-4 production in mice remains unclear, recent investigations have demonstrated that PGD₂ causes the preferential induction of IL-4 production by Th2 cells in humans by binding to CRTH2 (38, 39). Additionally, our recent report showing that CRTH2 signals up-regulate CD40L in resting human Th2 cells supports our conclusions because the engagement of CD40 by CD40L is also essential for IgE isotype switching (39, 40).

After intranasal sensitization with Cry j 1, CRTH2^{-/-} mice developed a weaker eosinophilia than did WT BALB/c mice. This suggests that CRTH2 mediates local eosinophil recruitment in this model, which agrees with reports showing that CRTH2 activation leads to changes in eosinophil shape, chemotaxis, and degranulation in vitro (16, 18, 41). Additionally, recent investigations have revealed that CRTH2 plays a proinflammatory role in eosinophil chemotaxis into inflamed tissue in vivo (11, 12, 21, 24, 42). On the other hand, submandibular lymph node cells from WT and CRTH2^{-/-} mice produced similar amount of IL-5 after intranasal sensitization with Cry j 1. It is well known that IL-5 plays a critical role in eosinophilic inflammation, especially in mice (43). Although little is known about whether CRTH2 activation enhances IL-5 production in mice, CRTH2 activation on Th2 cells is known to induce IL-5 production in humans (38, 39). One explanation of why nasal eosinophilia was reduced in CRTH2^{-/-} mice irrespective of IL-5 production is that cognate interaction between PGD₂ and CRTH2 on eosinophils may have an additive effect on local eosinophil recruitment, primarily due to the action of IL-5. In fact, in a mouse model of asthma, nebulized DK-PGD₂, a CRTH2 agonist, exacerbates eosinophilic lung inflammation without changes in IL-5 content in lung (21).

CRTH2^{-/-} mice displayed a significantly lower frequency of both sneezing and nasal rubbing after the nasal challenge compared with the WT mice. Several molecules, including IL-5, CD80/CD86, H1, and CD39, have been shown to contribute to these symptoms via different mechanisms (38, 44–46). The present result suggests that activation of CRTH2 is also involved

in the symptoms of nasal hyperreactivity. In humans, nasal challenge with PGD₂ induces a sustained nasal obstruction but not sneezing or rhinorrhea (47). Whether murine mast cells express CRTH2 is not well known, and further investigations are needed to determine whether the effect of CRTH2 on nasal hyperreactivity is due to the control of Th2 responses or to a direct effect on mast cells.

Treatment with ramatroban, a CRTH2/TP dual antagonist, induced a reduction in several indicators of JCP such as sneezing, Cry j 1-specific IgG1 production, and Cry j 1-induced IL-4 production. It is known that ramatroban suppresses allergic responses including nasal signs both in vivo and in vitro (11, 24, 46, 48). For example, ramatroban significantly inhibited sneezing and nasal rubbing induced by Ag in actively sensitized C57BL/6 mice and guinea pigs (46, 48). Our present results are consistent with these reports and support the findings seen in CRTH2^{-/-} mice that suggest a proinflammatory role of CRTH2 in allergic rhinitis. On the other hand, treatment with ramatroban was less effective than CRTH2 deficiency in all parameters of investigation. One of the possible reasons is that ramatroban antagonizes not only CRTH2 but also TP. Since it is not fully elucidated whether signals through TP, especially in mice, are proinflammatory or antiinflammatory in allergic rhinitis, simultaneous blockage with TP may affect changes of the outcomes induced by CRTH2 antagonism.

In conclusion, we developed a novel model of murine allergic rhinitis that mimics pollinosis. Additionally, we found that CRTH2 plays an essential role in the initiation of allergic rhinitis in mice. These results suggest that this murine model will be useful for elucidating the pathophysiology of allergic rhinitis, especially JCP. These observations may provide a basis for developing therapeutic approaches for managing allergic rhinitis, specifically by inhibiting PGD₂-CRTH2 interactions in the nose of individuals with allergic rhinitis.

Acknowledgments

The authors thank Yuko Okano for her editorial assistance, and Ryohei Oya and Fumika Uno for their technical assistance in immunohistochemistry.

Disclosures

The authors have no financial conflicts of interest.

References

- Bousquet, J., V. P. Cauwenberge, and N. Khaltaev. 2001. ARIA Workshop Report 2: epidemiology and genetics. *J. Allergy Clin. Immunol.* 108 (Suppl.): S153-S161.
- Asher, M. I., S. Montefort, B. Björkstén, C. K. Lai, D. P. Strachan, S. K. Weiland, H. Williams, and the ISAAC Phase Three Study Group. 2006. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood. ISAAC Phases One and Three repeat multicountry cross-sectional surveys. *Lancet* 368: 733-743.
- Okuda, M. 2003. Epidemiology of Japanese cedar pollinosis throughout Japan. *Ann. Allergy Asthma Immunol.* 91: 288-296.
- Harold, S. N. 2005. Advances in upper airway diseases and allergen immunotherapy. *J. Allergy Clin. Immunol.* 115: 676-684.
- Okano, M., K. Nishizaki, M. Abe, M. M. Wang, T. Yoshino, A. R. Satoskar, Y. Masuda, and D. A. Harn. 1999. Strain-dependent induction of allergic rhinitis without adjuvant in mice. *Allergy* 54: 593-601.
- Van de Rijin, M., P. D. Mehlhop, A. Judkins, M. E. Rothenberg, A. D. Luster, and H. C. Oettgen. 1998. A murine model of allergic rhinitis: studies on the role of IgE in pathogenesis and analysis of the eosinophil influx elicited by allergen and eotaxin. *J. Allergy Clin. Immunol.* 102: 65-74.
- Farraj, A. K., J. R. Harkema, and N. E. Kaminski. 2004. Allergic rhinitis induced by intranasal sensitization and challenge with trimellitic anhydride but not with dinitrochlorobenzene or oxazolone in A/J mice. *Toxicol. Sci.* 79: 315-325.
- Murasugi, T., Y. Nakagami, T. Yoshitomi, K. Hirahara, M. Yamashita, Y. Taniguchi, M. Sakaguchi, and K. Ito. 2005. Oral administration of a T cell epitope inhibits symptoms and reactions of allergic rhinitis in Japanese cedar pollen allergen-sensitized mice. *Eur. J. Pharmacol.* 510: 143-148.
- Wang, Y., and C. T. McCusker. 2005. Interleukin-13-dependent bronchial hyper-responsiveness following isolated upper-airway allergen challenge in a murine model of allergic rhinitis and asthma. *Clin. Exp. Allergy* 35: 1104-1111.
- Harris, S. G., J. Padilla, L. Koumas, D. Ray, and R. P. Phipps. 2002. Prostaglandins as modulators of immunity. *Trends Immunol.* 23: 144-150.
- Shiraiishi, Y., K. Asano, T. Nakajima, T. Oguma, Y. Suzuki, T. Shiomu, K. Sayama, K. Niimi, M. Wakaki, and J. Kagyo. 2005. Prostaglandin D₂-induced eosinophilic airway inflammation is mediated by CRTH2 receptor. *J. Pharmacol. Exp. Ther.* 312: 954-960.
- Okano, M., T. Fujiwara, Y. Sugata, D. Gotoh, M. Yoshihisa, M. Sogo, W. Tanimoto, M. Yamamoto, R. Matsumoto, N. Eguchi, et al. 2006. Presence and characterization of PGD₂-related molecules in nasal mucosa of patients with allergic rhinitis. *Am. J. Rhinol.* 20: 342-348.
- Fujitani, Y., Y. Kanaoka, K. Aritake, N. Uodome, K. Okazaki-Hatake, and Y. Urade. 2002. Pronounced eosinophilic lung inflammation and Th2 cytokine release in human lipocalin-type prostaglandin D synthase transgenic mice. *J. Immunol.* 168: 443-449.
- Honda, K., M. Arima, G. Cheng, S. Taki, H. Hirata, F. Eda, F. Fukushima, B. Yamaguchi, M. Hatano, T. Tokuhisa, and T. Fukuda. 2003. Prostaglandin D₂ reinforces Th2 type inflammatory responses of airways to low-dose antigen through bronchial expression of macrophage-derived chemokine. *J. Exp. Med.* 198: 533-543.
- Okano, M., T. Fujiwara, M. Yamamoto, Y. Sugata, R. Matsumoto, K. Fukushima, T. Yoshino, K. Shimizu, N. Eguchi, M. Kuniwa, et al. 2006. Role of prostaglandin D₂ and E₂ terminal synthases in chronic rhinosinusitis. *Clin. Exp. Allergy* 36: 1028-1038.
- Hirai, H., K. Tanaka, O. Yoshie, K. Ogawa, K. Kenmotsu, Y. Takamori, M. Ichimasa, K. Sugamura, M. Nakamura, S. Takano, and K. Nagata. 2001. Prostaglandin D₂ selectively induces chemotaxis in Th2 helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. *J. Exp. Med.* 193: 255-261.
- Kostenis, E., and T. Ulven. 2006. Emerging roles of DP and CRTH2 in allergic inflammation. *Trends Mol. Med.* 12: 148-158.
- Gervais, F. G., R. P. G. Cruz, A. Chateaufort, S. Gale, N. Sawyer, F. Nantel, K. M. Metters, and G. P. O'Neill. 2001. Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD₂ receptors CRTH2 and DP. *J. Allergy Clin. Immunol.* 108: 982-988.
- Heinemann, A., R. Schuligoi, I. Sabroe, A. Hartnell, and B. A. Peskar. 2003. Δ^2 -Prostaglandin J₂, a plasma metabolite of prostaglandin D₂, causes eosinophil mobilization from the bone marrow and primes eosinophils for chemotaxis. *J. Immunol.* 170: 4752-4758.
- Shichij, M., H. Sugimoto, K. Nagao, H. Inabe, J. A. Encinas, K. Takeshita, and K. B. Bacon. 2003. Chemoattractant receptor-homologous molecule expressed on Th2 cells activation in vivo increases blood leukocyte counts and its blockade abrogates 13,14-dihydro-15-keto-prostaglandin D₂-induced eosinophilia in rats. *J. Pharmacol. Exp. Ther.* 307: 518-525.
- Spik, L., C. Brenuchon, V. Angeli, D. Staumont, S. Fleury, M. Capron, F. Trottein, and D. Dombrowicz. 2005. Activation of the prostaglandin D₂ receptor DP2/CRTH2 increases allergic inflammation in mouse. *J. Immunol.* 174: 3703-3708.
- Chevalier, E., J. Stock, T. Fisher, M. Dupont, M. Fric, H. Fargeau, M. Lepoint, S. Soler, S. Fabien, M. P. Pruniaux, et al. 2005. Cutting edge: Chemoattractant receptor-homologous molecule expressed on Th2 cells plays a restricting role on IL-5 production and eosinophil recruitment. *J. Immunol.* 175: 2056-2060.
- Nantel, F., C. Fong, S. Lamontagne, D. H. Wright, A. Giald, M. Desrosiers, K. M. Metters, G. P. O'Neill, and F. G. Gervais. 2004. Expression of prostaglandin D synthase and the prostaglandin D₂ receptors DP and CRTH2 in human nasal mucosa. *Prostaglandins Other Lipid Mediat.* 73: 87-101.
- Sato, T., R. Moroi, K. Aritake, Y. Urade, Y. Kanai, K. Sumi, H. Yokozaki, H. Hirai, K. Nagata, T. Hara, et al. 2006. Prostaglandin D₂ plays an essential role in chronic allergic inflammation of the skin via CRTH2 receptor. *J. Immunol.* 177: 2621-2629.
- Okano, M., Y. Sugata, T. Fujiwara, R. Matsumoto, M. Nishibori, K. Shimizu, M. Maeda, Y. Kimura, S. Kariya, H. Hattori, et al. 2006. F. prostanoic acid (EP2)/EP4-mediated suppression of antigen-specific human T cell responses by prostaglandin E₂. *Immunology* 118: 343-352.
- Okano, M., H. Hattori, T. Yoshino, Y. Sugata, M. Yamamoto, T. Fujiwara, A. R. Satoskar, A. A. Satoskar, and K. Nishizaki. 2005. Nasal exposure to Staphylococcal enterotoxin enhances the development of allergic rhinitis in mice. *Clin. Exp. Allergy* 35: 506-514.
- Enander, B., and S. Ahlstedt. 1983. Regional and systemic immune responses to trinitrophenyl derivatives after intranasal and subcutaneous sensitization of mice. *J. Allergy Clin. Immunol.* 71: 293-299.
- Sakurai, K., H. Takenaka, Y. Yoneda, J. Tashiro-Yamaji, Y. Yamamoto, K. Lee, S. Yamaguchi, M. Miyoshi, Y. Kubota, and R. Yoshida. 2005. IgE production after four routes of injections of Japanese cedar pollen allergen without adjuvant: crucial role of resident cells at intraperitoneal or intranasal injection site in the production of specific IgE toward the allergen. *Microbiol. Immunol.* 49: 433-441.
- Tamura, S., Y. Shoji, K. Hashiguchi, C. Aizawa, and T. Kurata. 1994. Effects of cholera toxin adjuvant on IgE antibody response to orally or nasally administered ovalbumin. *Vaccine* 12: 1238-1239.
- Bonford, R. 1980. The comparative selectivity of adjuvants for humoral and cell-mediated immunity. I. Effect of the antibody response to bovine serum albumin and sheep red blood cells of Freund's incomplete and complete adjuvants, alhydrogel, Corynebacterium parvum, Bordetella pertussis, muramyl dipeptide and saponin. *Clin. Exp. Immunol.* 39: 426-434.
- Valensi, J. P. M., J. R. Carlson, and V. G. A. Nest. 1994. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. *J. Immunol.* 153: 3929-3939.

32. Okano, M., K. Nishizaki, A. R. Satoskar, T. Yoshino, Y. Masuda, and D. A. Harn. 1999. Involvement of carbohydrate on phospholipase A2, a bee-venom allergen, in in vivo antigen-specific IgE synthesis in mice. *Allergy* 54: 811–818.
33. Cosmi, L., F. Annunziato, M. Iasak, G. Galli, R. M. E. Maggi, K. Nagata, and S. Romagnani. 2000. CRTH2 is the most reliable marker for the detection of circulating human type 2 Th and type 2 T cytotoxic cells in health and disease. *Eur. J. Immunol.* 30: 2972–2979.
34. Iwasaki, M., K. Nagata, S. Takano, K. Takahashi, N. Ishii, and Z. Ikezawa. 2002. Association of a new-type prostaglandin D₂ receptor CRTH2 with circulating T helper 2 cells in patients with atopic dermatitis. *J. Invest. Dermatol.* 119: 609–616.
35. Hijinen, D., E. Nijhuis, M. Bruin-Weller, F. Holstege, M. G. Koerkamp, I. Kok, C. Bruijnzeel-Koomen, and E. Knol. 2005. Differential expression of genes involved in skin homing, proliferation, and apoptosis in CD4⁺ T cells of patients with atopic dermatitis. *J. Invest. Dermatol.* 125: 1149–1155.
36. Snapper, C. M., and W. E. Paul. 1987. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. *Science* 236: 944–947.
37. Okano, M., T. Yoshino, K. Nishizaki, A. R. Satoskar, F. Brombacher, A. A. Satoskar, M. Abe, Y. Takeda, and D. A. Harn. 2000. Interleukin-4 independent production of Th2 cytokines by nasal lymphocytes and nasal eosinophilia in murine allergic rhinitis. *Allergy* 55: 723–731.
38. Xue, L., S. L. yles, F. R. Wetley, I. Gazi, E. Townsend, M. G. Hunter, and R. Pettipher. 2005. Prostaglandin D₂ causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells. *J. Immunol.* 175: 6531–6536.
39. Tanaka, K., H. Hirai, S. Takano, M. Nakamura, and K. Nagata. 2004. Effects of prostaglandin D₂ on helper T cell functions. *Biochem. Biophys. Res. Commun.* 316: 1009–1014.
40. Hattori, H., M. Okano, S. Kariya, K. Nishizaki, and A. R. Satoskar. 2006. Signals through CD39 play a critical role in the pathophysiology of *Schistosoma mansoni* egg antigen-induced allergic rhinitis in mice. *Am. J. Rhinol.* 20: 165–169.
41. Monneret, G., S. Gravel, M. Diamond, J. Rokach, and W. S. Powell. 2001. Prostaglandin D₂ is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. *Blood* 98: 1942–1948.
42. Almishri, W., C. Cossette, J. Rokach, J. G. Martin, Q. Hamid, and W. S. Powell. 2005. Effects of prostaglandin D₂, 15-deoxy- $\Delta^{12,14}$ -prostaglandin J₂, and selective DP₁ and DP₂ receptor agonists on pulmonary infiltration of eosinophils in Brown Norway rats. *J. Pharmacol. Exp. Ther.* 313: 64–69.
43. Foster, P. S., S. P. Hogan, A. J. Ramsay, K. I. Maestrelli, and I. G. Young. 1996. Interleukin-5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. *J. Exp. Med.* 183: 195–201.
44. Asakura, K., H. Saito, M. Watanabe, H. Ogasawara, T. Matsui, and A. Kataura. 1998. Effects of anti-IL-5 monoclonal antibody on the murine model of nasal allergy. *Int. Arch. Allergy Immunol.* 116: 49–52.
45. Sato, J., K. Asakura, M. Murakami, T. Ueda, and A. Kataura. 1999. Suppressive effects of CTLA4-Ig on nasal allergic reactions in presensitized murine model. *Life Sci.* 64: 785–795.
46. Kayasuga, R., Y. Sugimoto, T. Watanabe, and C. Kamei. 2002. Participation of chemical mediators other than histamine in nasal allergy signs: a study using mice lacking histamine H₁ receptors. *Eur. J. Pharmacol.* 449: 287–291.
47. Doyle, W. J., S. Boehm, and D. P. Skoner. 1990. Physiologic responses to intranasal dose-response challenges with histamine, methacholine, bradykinin, and prostaglandin in adult volunteers with and without nasal allergy. *J. Allergy Clin. Immunol.* 86: 924–935.
48. Narita, S., K. Asakura, and A. Kataura. 1996. Effects of thromboxane A2 receptor antagonist (Bay u 3395) on nasal symptoms after antigen challenge in sensitized guinea pigs. *Int. Arch. Allergy Immunol.* 109: 161–166.

Allergen-specific immunotherapy alters the expression of B and T lymphocyte attenuator, a co-inhibitory molecule, in allergic rhinitis

M. Okano*, N. Otsuki^{†1}, M. Azuma[†], T. Fujiwara*, S. Kariya*, Y. Sugata*², T. Higaki*, K. Kino[†], Y. Tanimoto[§], K. Okubo^{†1} and K. Nishizaki*

*Department of Otolaryngology – Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan,

[†]Department of Molecular Immunology, Tokyo Medical and Dental University, Tokyo, Japan, [‡]Division of Research and Development, Meiji Dairies Corporation,

Odawara, Japan, [§]Department of Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan,

and ¹Department of Otolaryngology, Nippon Medical School, Tokyo, Japan

Clinical and Experimental Allergy

Summary

Background B7/CD28 family co-signalling molecules play a key role in regulating T cell activation and tolerance. Allergen-specific immunotherapy (SIT) alters allergen-specific T cell responses. However, the effect of SIT on the expression of various co-signalling molecules has not been clarified.

Objective We sought to determine whether SIT might affect the expression of three co-inhibitory molecules, programmed death (PD)-1, B7-H1 and B and T lymphocyte attenuator (BTLA), in Japanese cedar pollinosis (JCP).

Methods Peripheral blood mononuclear cells (PBMCs) were isolated from JCP patients who had or had not received SIT. PBMC were cultured in the presence or absence of Cry j 1, after which the cell surface expression of PD-1, B7-H1 and BTLA, as well as IL-5 production, were determined. In addition, the effect of BTLA cross-linking on IL-5 production was examined.

Results After Cry j 1 stimulation, no significant differences in PD-1 and B7-H1 expression were observed between SIT-treated and SIT-untreated patients. BTLA expression was down-regulated in untreated patients after Cry j 1 stimulation and up-regulated in SIT-treated patients. Up-regulation of BTLA in SIT-treated patients was particularly apparent in a CD4⁺ T cell subset. IL-5 production was clearly reduced among SIT-treated patients, and the observed changes in BTLA expression correlated negatively with IL-5 production. Moreover, immobilization of BTLA suppressed IL-5 production in JCP patients.

Conclusion These results suggest that both IL-5 production and down-regulation of BTLA in response to allergen are inhibited in SIT-treated patients with JCP. BTLA-mediated co-inhibition of IL-5 production may contribute to the regulation of allergen-specific T cell responses in patients receiving immunotherapy.

Keywords allergen immunotherapy, allergic rhinitis, BTLA, Cry j 1, IL-5

Submitted 18 February 2008; revised 18 August 2008; accepted 3 September 2008

Correspondence:

Mitsuhiro Okano, Department of Otolaryngology – Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikatacho, Okayama 700-8558, Japan. E-mail: mokano@cc.okayama-u.ac.jp

Cite this as: M. Okano, N. Otsuki, M. Azuma, T. Fujiwara, S. Kariya, Y. Sugata, T. Higaki, K. Kino, Y. Tanimoto, K. Okubo and K. Nishizaki, *Clinical and Experimental Allergy*, 2008 (38) 1891–1900.

Introduction

Allergen-specific immunotherapy (SIT) is an effective treatment for IgE-mediated, type 2 T helper (Th2)-biased

allergic diseases, particularly allergic rhinitis [1]. Unlike pharmacotherapy, SIT is unique in that it can alter the natural course of allergic disease by preventing new sensitization/onset and providing long-term remission after discontinuation of treatment [2–4].

A number of studies have shown that SIT alters allergen-specific T cell responses resulting in immune tolerance [1, 5]. For example, SIT suppresses allergen-specific Th2 immunity, including IL-4 and IL-5 production,

¹Present address: Institute of Medical Science, University of Tokyo, Tokyo, Japan.

²Present address: Department of Otolaryngology, Iwakuni Clinical Center, Iwakuni, Japan.

systemically and at local sites [6–8]. SIT alters the immune response to favour Th1 immunity, such as IFN- γ production [9]. In addition, SIT induces immune suppression by activating regulatory T cells and cytokines, such as IL-10 and TGF- β [5, 10].

The activation, proliferation and cytokine production of antigen-specific T cells are regulated by two distinct signals from antigen-presenting cells (APC) [11, 12]. The first signal is provided by interaction of the antigen/major histocompatibility complex with a T cell receptor (TCR). The second signal is delivered by co-signalling molecules. Among these, molecules from the B7/CD28 family play a key role in the regulation of T cell activation and tolerance [12]. B7-1 (CD80) and B7-2 (CD86), as well as their ligands (CD28 and CTLA-4) were the first-discovered B7/CD28 family molecules and therefore have been the most extensively characterized in allergic rhinitis [13–15]. For example, we have previously shown that the expression of both CD80 and CD86 is increased within the nasal mucosa of patients with perennial allergic rhinitis, compared with control subjects following nasal provocation with house dust [14].

In addition to the original B7/CD28 family molecules, new B7 family members, such as inducible co-stimulator (ICOS) L, programmed death (PD)-L1, PD-L2, B7-H3 and B7-H4, have been identified [12]. New CD28 family members, including ICOS, PD-1 and B and T lymphocyte attenuator (BTLA), have also been identified [12]. Among the new CD28 family members, ICOS delivers a range of co-stimulatory signals that augment T cell differentiation and cytokine production and provide critical signals for Ig production [12, 16]. Conversely, both PD-1 and BTLA possess an immunoreceptor tyrosine-based inhibition motif (ITIM) within their cytoplasmic domain, and display co-inhibitory signals that suppress T cell activation [17, 18]. One report has demonstrated enhanced CD86 expression in CD14⁺ cells after recall stimulation with PLA₂ in patients exposed to bee-venom SIT, as well as suppressed IL-10 production by peripheral blood mononuclear cell (PBMC) following blockade with CD86 in patients exposed to SIT [19]. However, little is known regarding the potential role of co-inhibitory molecules in these responses to SIT.

In the present study, we investigated the expression and characteristics of the co-inhibitory molecules, PD-1 and BTLA, along with B7-H1 (a ligand of PD-1), in allergen-stimulated PBMC from patients with Japanese cedar pollinosis (JCP). We believe that the findings presented here are the first to demonstrate altered BTLA expression in response to Cry j 1, the major allergen of *Cryptomeria japonica* pollen, potentially explaining the beneficial effect of SIT in JCP and providing a basis for future therapeutic approaches aimed at the regulation of BTLA expression to limit allergic diseases.

Materials and methods

Antigens and reagents

Cry j 1 was purified and concentrated from the crude extracts of *C. japonica* pollen, as previously described [20]. The fluorescein isothiocyanate (FITC)-labelled anti-human PD-1 (clone MIH4, mouse IgG1), B7-H1 (clone MIH1, mouse IgG1) and BTLA (clone MIH27, mouse IgG2b) were generated as previously described [21, 22]. The purification of anti-human BTLA (clone MIH26, mouse IgG2b) is also described elsewhere [22]. Cy5-labelled anti-human CD4, PE-labelled anti-human CD8 and CD19, as well as their respective control mouse IgG isotypes, were purchased from BD Biosciences (San Jose, CA, USA). Biotinylated anti-human CD203c mAb (FR3-16A11), anti-biotin microbeads and MS columns were purchased from Miltenyi Biotec GmbH (Bergisch Gladbach, Germany).

Patients

Twenty-one patients with JCP (three males and 18 females: aged 21–57, mean age 42.9 years) were enrolled in the study. Written informed consent was obtained from each subject. Sensitization to Japanese cedar pollen was confirmed by the presence of specific-IgE antibodies, as determined by CAP (Pharmacia, Uppsala, Sweden), ranging in concentration from 1.8 to >100 UA/mL (mean 21.3 \pm 27.2). Eleven patients received SIT using a standardized extract of *C. japonica* pollen (Torii Co., Tokyo, Japan) over a period of at least 2 years. A maintenance concentration of 2000 JAU/mL was archived in all the patients treated with SIT. The mean maintenance dose of the extract was 509.0 JAU. None of the patients had used immunosuppressive drugs, including oral steroids, during the pollen season. No significant differences in age or sex existed among the SIT-treated and untreated patients. Clinical characteristics of groups of patients are shown in Table 1. Comparison of naso-ocular symptoms and rhinitis-related quality of life (QOL) during the pollen-dispersed season between SIT-treated patients and SIT-untreated patients using JRQLQ No.1, the Japanese QOL questionnaire for allergic rhinitis [23]. The study was approved by the Human Research Committee of Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.

Detection of PD-1, B7-H1 and B and T lymphocyte attenuator expression

Heparinized blood was sampled during the season when pollen is dispersed. The PBMCs were then isolated and cultured as previously described [20]. In brief, PBMCs (2 \times 10⁶/mL) were incubated in the presence or absence of 10 μ g/mL of Cry j 1 at 37 °C in a 5% CO₂/air mixture for

Table 1. Subject characterization

	SIT patients		Non-SIT patients	
No. of patients	11		10	
Sex (male/female)	0/11		3/7	
Age (years)	47 (36–57)		38 (21–53)	
	At enrollment	2008	At enrollment	2008
CAP titre to JCP (UA/mL)	19.6 (1.8–81.1)	16.6 (0–61.3)	23.1 (1.8–100)	30.5 (6.5–100)
Total IgE (IU/mL)	105 (4–232)	161 (0–458)	145 (27–303)	135 (44–304)
Blood eosinophil (μL^{-1})	306 (43–655)	298 (79–532)	205 (48–725)	218 (69–592)

SIT, specific immunotherapy-treated patients; non-SIT, SIT-untreated patients; JCP, Japanese cedar pollinosis.

72 h. Less than 5% of cultured cells had died as judged by trypan blue exclusion test, indicating high cell viability of cultured cells. After incubation, Cry j 1-stimulated and Cry j 1-unstimulated PBMCs were harvested, blocked and stained with FITC-labelled anti-PD-1, B7-H1 or BTLA, as well as PE-labelled anti-CD8, Cy5-labelled anti-CD4, and CD19, in addition to isotype-matched control Abs [13]. The cells were washed and analysed with FACScan equipment using CellQuest software (BD Biosciences). Lymphocytes were gated according to forward scatter and side scatter and at least 10 000 events were acquired and analysed. Cry j 1-induced expression was determined and the percentage of positive cells in cultured PBMC following Cry j 1 stimulation was subtracted from the percentage observed in unstimulated PBMC. To avoid experimental bias, the laboratory investigators were blinded to the sample origin.

Measurement of cytokines

Supernatant was collected after 12 and 72 h of culture and stored at -80°C until it was used for assay. Levels of IL-5, IL-10 and TGF- β were measured within each sample of culture supernatant by means of Opt EIA sets (BD Biosciences), in accordance with the manufacturer's instructions. Levels of IL-10 were further measured in supernatant after 12 h of culture. The detection limits of these assays were 5 pg/mL for IL-5, 5 pg/mL for IL-10 and 20 pg/mL for TGF- β . Cry j 1-induced production was determined by subtracting the cytokine levels measured following Cry j 1 stimulation from those measured in the absence of stimulation. In order to determine whether the productions were due to basophil responsiveness, containing basophils were removed from PBMC by immunomagnetic negative selection using biotinylated anti-human CD203c mAb (FR3-16A11), anti-biotin microbeads and MS columns. Complete depletion of basophils was confirmed by Kimura's staining [24].

Proliferative responses

After 72 h of incubation with or without Cry j 1, proliferative responses were measured by means of BrdU

incorporation (Roche Diagnostics GmbH, Mannheim, Germany) in accordance with the manufacturer's instructions. Proliferation was estimated by the stimulation index calculated as follows: the ratio between mean OD at 450 nm obtained in the culture with Cry j 1 and that obtained in the antigen-free culture.

Cross-linking of B and T lymphocyte attenuator

PBMCs ($2 \times 10^6/\text{mL}$) from JCP patients without SIT were stimulated with 10 $\mu\text{g}/\text{mL}$ of Cry j 1 in the presence of immobilized anti-BTLA mAb (MIH26) or control mouse IgG2b. Immobilization was performed by incubation of 20 $\mu\text{g}/\text{mL}$ of each Ab diluted in PBS, followed by washing using complete culture medium as previously described [22]. After 72 h of incubation, IL-5 production and proliferation were determined as described above.

Statistical analysis

The non-parametric Wilcoxon's signed-rank test and Mann-Whitney's *U*-test were used. Correlation analysis was performed using Spearman's correlation coefficient by rank. A level of $P < 0.05$ was considered statistically significant. Values were given as means \pm standard deviation. Statistical analysis was performed using Stat-ViewTM software (version 4.5; Abacus Inc., Berkeley, CA, USA).

Results

Clinical efficacy of specific immunotherapy in Japanese cedar pollinosis

Analysis using JRQLQ revealed that cedar immunotherapy was clinically effective against not only naso-ocular symptoms but also rhinitis-related QOL in SIT-treated patients in two consecutive seasons (Fig. 1). Levels of serum total IgE ($P = 0.360$), JCP-specific IgE titre ($P = 0.725$) and blood eosinophil counts ($P = 0.205$) were similar between SIT-treated and SIT-untreated patients at the enrollment of the study. And these levels were still




Fig. 1. Effect of cedar immunotherapy on symptom and quality of life (QOL) in Japanese cedar pollinosis (JCP). Naso-ocular symptoms (a, b) and rhinitis-related QOL (c, d) were compared between specific immunotherapy (SIT)-treated patients (closed square) and SIT-untreated patients (open circle) during the pollen-dispersed season in 2005 (a, c) and 2006 (b, d). The x-axis denotes weeks after the onset of cedar and cypress pollen dispersion. The y-axis denotes scores. The P-values were determined using the Mann-Whitney's U-test.

similar between the groups in 2008 (serum total IgE: $P=0.833$, JCP-specific IgE titre: $P=0.205$, blood eosinophil counts: $P=0.181$). However, the levels of JCP-specific IgE titre in 2008 were significantly elevated as compared with those at the enrollment in SIT-untreated group ($P=0.011$) whereas the levels between before- and after-treatment were not significantly different in SIT-treated group ($P=0.790$) (Table 1).

Changes in co-inhibitory molecule expression in response to Cry j 1 in peripheral blood mononuclear cells from patients with Japanese cedar pollinosis

The percentage of cells expressing PD-1, B7-H1 and BTLA in PBMC after exposure or no exposure to *in vitro* Cry j 1 stimulation is summarized in Table 2. The baseline expression of these molecules in the absence of Cry j 1 stimulation was similar among SIT-treated and SIT-untreated patients. In addition, the percentage of positive cells observed after stimulation with Cry j 1 did not differ

Table 2. Percentage of positive cells expressing co-inhibitory molecules with or without Ag stimulation

Molecule	Stimulation	SIT (n = 11)	Non-SIT (n = 10)	P-value
PD-1	Ag (-)	1.06±0.86	0.86±0.72	0.860
	Ag (+)	1.66±1.47	1.51±1.49	0.888
	Change	0.60±0.74	0.65±1.03	0.805
B7-H1	Ag (-)	1.08±1.07	0.97±0.95	0.778
	Ag (+)	1.55±1.45	1.06±1.04	0.481
	Change	0.47±0.48	0.09±0.90	0.067
BTLA	Ag (-)	2.73±2.50	4.91±4.22	0.460
	Ag (+)	3.70±2.87	2.67±2.33	0.503
	Change	0.97±1.17	-2.24±2.21	<0.001

SIT, specific immunotherapy-treated patients; non-SIT, SIT-untreated patients; PD, programmed death; BTLA, B and T lymphocyte attenuator.

significantly in each molecule. However, when we focused on changes in expression in response to Cry j 1 in each patient, BTLA expression was reduced in SIT-untreated patients, but not in SIT-treated patients (Fig. 2).




Fig. 2. Typical histogram of B and T lymphocyte attenuator (BTLA) expression. Peripheral blood mononuclear cells (PBMCs) from SIT-treated (a, b) and SIT-untreated (c, d) patients were incubated in the presence or absence of Cry j 1 for 72 h. After incubation, Cry j 1-stimulated (b, d) and unstimulated (a, c) PBMC were harvested, blocked and stained with FITC-labelled anti-BTLA mAb (MIH27, open histogram) or control mouse IgG2b (shaded histogram). Lymphocytes were gated according to forward scatter and side scatter and at least 10 000 events were acquired and analysed. The x-axis (log scale) shows fluorescence intensity and y-axis shows cell counts. SIT, specific immuno therapy-treated patients; non-SIT, SIT-untreated patients, FITC, fluorescein isothiocyanate.

Significantly different responses in terms of BTLA expression following Cry j 1 stimulation were observed among SIT-treated and untreated patients ($P < 0.001$). A tendency toward enhanced B7-H1 expression was seen in SIT-treated patients, compared with untreated patients ($P = 0.067$). On the other hand, changes in PD-1 expression did not differ among patients from both groups ($P = 0.805$) (Table 2).

Phenotype analysis of cells expressing co-inhibitory molecules

BTLA is known to be expressed on both B and T cells. In SIT-treated patients, the percentage of CD4⁺ cells expressing BTLA was significantly increased after recall stimulation with Cry j 1 ($P = 0.003$, Fig. 3a). Conversely, the

percentage was significantly reduced in SIT-untreated patients ($P = 0.017$, Fig. 3d). On the other hand, a significant change in BTLA expression on CD8⁺ cells was not observed in either SIT-treated ($P = 0.154$) or SIT-untreated ($P > 0.999$) patients (Figs 3b and e). A reduced expression on CD19⁺ cells was observed in both SIT-treated ($P = 0.091$) and SIT-untreated ($P = 0.037$) patients following stimulation (Figs 3c and f).

PD-1 and B7-H1 are also known to be expressed on both B and T cells. The percentage of CD4⁺ ($P = 0.037$) but not CD8⁺ ($P = 0.161$) or CD19⁺ ($P = 0.110$) cells expressing PD-1 was significantly increased in SIT-treated patients after recall stimulation with Cry j 1 (Figs 4a–c). On the other hand, a tendency toward enhanced PD-1 expression on CD4⁺ ($P = 0.086$) and CD19⁺ ($P = 0.093$) but not CD8⁺ ($P > 0.999$) cells was seen in SIT-untreated




Fig. 3. Phenotype analysis of cells expressing B and T lymphocyte attenuator (BTLA). The peripheral blood mononuclear cells (PBMCs) from patients with (a–c) or without (d–f) specific immunotherapy (SIT) were incubated in the presence or absence of Cry j 1 for 72 h, after which the percentage of CD4⁺ (a, d), CD8⁺ (b, e) and CD19⁺ (c, f) cells expressing BTLA in cultured PBMC was determined by flow cytometry. The *P*-values were determined using the Wilcoxon's signed-rank test.




Fig. 4. Phenotype analysis of cells expressing programmed death (PD)-1. The peripheral blood mononuclear cells (PBMCs) from patients with (a–c) or without (d–f) specific immunotherapy (SIT) were incubated in the presence or absence of Cry j 1 for 72 h, after which the percentage of CD4⁺ (a, d), CD8⁺ (b, e) and CD19⁺ (c, f) cells expressing PD-1 in cultured PBMC was determined by flow cytometry. The *P*-values were determined using the Wilcoxon's signed-rank test.

patients (Figs 4d–f). Although a tendency toward overall enhanced B7-H1 expression after recall stimulation with Cry j 1 was seen in SIT-treated patients as compared with untreated patients (Table 2), Cry j 1-induced changes of B7-H1 expression on CD4⁺, CD8⁺ or CD19⁺ cells were not significant in either SIT-treated or SIT-untreated patients (data not shown).

Correlation between Cry j 1-induced interleukin-5 production and changes in B and T lymphocyte attenuator expression

After 72 h of incubation, levels of Cry j 1-induced IL-5 production were significantly reduced in PBMC from SIT-treated patients, compared with untreated patients




Fig. 5. Comparison of Cry j 1-induced cytokine production and proliferation among specific immunotherapy (SIT)-treated and SIT-untreated Japanese cedar pollinosis (JCP) patients. Peripheral blood mononuclear cells (PBMCs) were incubated in the presence or absence of Cry j 1 for 72 h, after which the levels of IL-5 (a), IL-10 (b) and TGF- β (c) were determined within the supernatant by ELISA. Changes in production were determined by measuring the differences between the levels observed following Cry j 1 stimulation and those observed in the absence of stimulation. In addition, Cry j 1-induced PBMC proliferation was measured by BrdU incorporation (d). *P*-values were determined using the Mann-Whitney's *U*-test. SIT represents the patients treated with SIT. Non-SIT represents SIT-untreated group of patients.

($P=0.007$, Fig. 5a). On the other hand, IL-10 or TGF- β production in response to Cry j 1 was not detected in either group (Figs 5b and c). IL-10 production was not detected even after 12 h incubation with Cry j 1. Cry j 1-induced IL-5 production was similar between basophil-depleted PBMC (121.9 ± 77.9 pg/mL) and control PBMC (128.9 ± 59.6 pg/mL, $P=0.624$), suggesting that basophil responsiveness in IL-5 production is negligible in our culture system. A trend of suppression in Cry j 1-induced proliferation was seen in PBMC from SIT-treated patients as compared with those from SIT-untreated patients ($P=0.057$; Fig. 5d).

Interestingly, the observed Cry j 1-induced changes in BTLA expression were significantly and negatively correlated with IL-5 production ($\rho=-0.747$, $P<0.001$; Fig. 6). However, when we analysed the correlation separately, the correlation was not seen in either SIT-treated ($\rho=-0.243$, $P=0.416$) or SIT-untreated ($\rho=-0.491$, $P=0.141$) group because Cry j 1-induced IL-5 production was lost in most of SIT-treated patients. The changes in Cry j 1-induced IL-5 production were significantly and positively correlated with both naso-ocular symptom scores ($\rho=0.616$, $P=0.024$) and QOL scores ($\rho=0.719$, $P=0.008$). The




Fig. 6. Relationship between Cry j 1-induced B and T lymphocyte attenuator (BTLA) expression and IL-5 production. Peripheral blood mononuclear cells (PBMCs) were incubated in the presence or absence of Cry j 1 for 72 h, after which the expression of BTLA and IL-5 levels were determined by flow cytometry and ELISA, respectively. Specific immunotherapy (SIT)-treated and SIT-untreated Japanese cedar pollinosis (JCP) patients are represented by the open circles and closed triangles, respectively.

changes in BTLA expression did not correlate with naso-ocular symptom scores ($\rho=-0.063$, $P=0.760$); however, the changes showed a tendency to inversely correlate with QOL scores ($\rho=-0.450$, $P=0.067$).

Effect of B and T lymphocyte attenuator cross-linking on Cry j 1-induced interleukin-5 production

Finally, we sought to determine the *in vitro* role of BTLA in Cry j 1-specific PBMC responses. Immobilized anti-BTLA mAb significantly suppressed Cry j 1-induced IL-5 production by PBMC, compared with control mouse IgG2b ($P=0.016$; Fig. 7a). On the other hand, Cry j 1-induced proliferative responses were not different between immobilized anti-BTLA mAb and the control treatment ($P=0.879$; Fig. 7b).

Discussion

The key finding of the present study was that BTLA expression is down-regulated after Cry j 1 stimulation in patients not treated with SIT, while it is up-regulated in SIT-treated patients. The up-regulation of BTLA in SIT-treated patients was particularly apparent in a CD4⁺ T cell subset. Cry j 1-induced changes in BTLA expression were significantly and inversely correlated with IL-5 production by PBMC. Furthermore, cross-linking of BTLA resulted in inhibition of Cry j 1-induced IL-5 production. These results suggest that both IL-5 production and down-regulation of BTLA in response to allergen are inhibited in SIT-treated patients with JCP.




Fig. 7. Effect of cross-linking of B and T lymphocyte attenuator (BTLA) on Cry j 1-induced responses in peripheral blood mononuclear cells (PBMCs). PBMC from patients with Japanese cedar pollinosis (JCP) without immunotherapy were incubated in the presence or absence of Cry j 1, along with either MH26 or control mouse IgG2b, for 72 h, after which levels of Cry j 1-induced IL-5 (a) and proliferative responses (b) were determined. *P*-values were determined using the Wilcoxon's signed-rank test.

BTLA is a recently identified member of the CD28 family of receptors. Similar to PD-1 and CTLA-4, BTLA contains ITIMs, suggesting that BTLA functions as an inhibitory receptor [17]. In fact, reduced BTLA expression leads to enhanced T cell and B cell responses in mice [17, 25]. However, little is known regarding the potential role of BTLA in human cellular responses. We have previously demonstrated that BTLA ligation inhibits anti-CD3-stimulated proliferation as well as the production of IFN- γ and IL-10 in human CD4⁺ T cells [22]. Another group has reported suppression of anti-CD3-induced proliferation in response to cross-linking of BTLA, and reduced expression of CD25 and production of IL-2 and IL-4 in addition to IFN- γ and IL-10 in human T cells [26]. In the present study, immobilized anti-BTLA mAb that can cross-link BTLA significantly suppressed Cry j 1-induced IL-5 production by PBMC. This result is consistent with previous reports, and demonstrates for the first time that cross-linking of BTLA also inhibits antigen-specific human PBMC responses. On the other hand, BTLA cross-linking did not alter Cry j 1-induced proliferative responses. We have previously shown that BTLA-induced inhibitory signals depend on the strength of TCR signals [22]. These results suggest that BTLA cross-linking selectively affects Cry j 1-induced IL-5 production in our system. Although, to date, no Ab to block human BTLA is available, the definitive experiment would be to block BTLA (with non-cross-linking Abs or Fab fragments) to see if IL-5 production is restored in SIT patients.

Antigen concentration is one of the key factors regulating *in vitro* cellular responses. We previously reported that PBMC showed proliferative responses to Cry j 1 in a dose-dependent manner, and the samples showed positive responses at 10 μ g/mL [20]. Another investigation used Cry j 1 at the concentration of 25–50 μ g/mL with substantial results [27]. Thus, we think that the concentration

of 10 μ g/mL of Cry j 1 is appropriate concentration used in the present study.

Similar to other co-stimulatory molecules, the expression of BTLA is known to change upon activation [22, 25, 26, 28]. The expression of BTLA is up-regulated on T cells and down-regulated on B cells upon activation in mice [25, 28]. In humans, we have demonstrated constitutive BTLA expression on the surface of both CD4 and CD8T cells at high levels, which gradually declines after stimulation with anti-CD3 and anti-CD28 mAb [22]. The relationship between BTLA expression and pathogenesis has been investigated in several human diseases [26, 29, 30]. For example, increased BTLA expression has been demonstrated on CD4⁺ and CD8⁺ T cells within pleural fluid in lung cancer patients [26]. An association between a BTLA gene polymorphism and risk of rheumatoid arthritis has also been reported [29]. The baseline expression of BTLA did not differ significantly among SIT-treated and SIT-untreated patients. However, down-regulation of BTLA was only observed in untreated patients in the present study. Although the precise mechanism by which the expression of BTLA is down-regulated remains unknown, signals through the TCR, as well as cytokines produced by Cry j 1-specific T cells and/or pro-inflammatory cytokines/chemokines secreted by monocytes or B cells may all function to regulate BTLA expression. Identification of mechanism regulating BTLA expression must be made in future investigation.

BTLA was originally cloned from murine Th1 cells, and is predominantly expressed by B cells, followed by T cells and APC in mice [17, 25]. In humans, we have recently reported BTLA expression on CD4⁺ T cells, CD8⁺ T cells and CD19⁺ B cells in freshly isolated human PBMC. Unlike in mice, polarized human Th1 and Th2 cells consist of both BTLA-positive and BTLA-negative populations; however, BTLA expression diminishes with extended length of culture [22]. The present results are consistent with those of previous reports and suggest that BTLA expression persists on human CD4⁺, CD8⁺ and CD19⁺ cells during short-term culture. Furthermore, only CD4⁺ cells bearing BTLA were significantly increased after recall stimulation with Cry j 1, suggesting that SIT selectively enhances BTLA expression on CD4⁺ T cells.

A significant difference in Cry j 1-induced IL-5 production by PBMC was seen among SIT-treated and untreated patients. Inhibition of both local and systemic IL-5 production is known to correlate with clinical efficacy [6, 8]. The present result is consistent with a report by Kakinoki et al. [6] demonstrating that the production of IL-5 following Cry j 1-stimulation by PBMC is significantly reduced in good responders, compared with poor responders to SIT in patients with JCP. On the other hand, Cry j 1-induced IL-10 and TGF- β production was not detected in PBMC from SIT-treated patients. One of the reasons why IL-10 production was not induced in our immunotherapy

is that, although our immunotherapy was clinically effective (Fig. 1) and 2000 JAU/mL of JPC extract is maximal concentration commercially available in Japan, the maintenance dose is relatively low (the mean maintenance dose of the extract was 509.0 JAU which is equivalent to 0.37–1.07 µg of Cry j 1) as compared with other reports [1–5]. Moreover, the observed changes in BTLA expression were significantly and negatively correlated with IL-5 production after Cry j 1-stimulation in the present study. This result confirms the result of our cross-linking study and suggests that BTLA has an inhibitory role with regard to Cry j 1-specific IL-5 production in JCP.

In the present study, the expression of co-inhibitory molecules and cytokine production was determined during the pollen season after at least 2 years of SIT treatment. It is interesting to determine the effect of SIT during the first pollen season after starting this therapy. Our preliminary results showed that, as compared with SIT-untreated patients ($n = 10$), PBMC from the newly SIT-treated patients during the first pollen season after starting cedar immunotherapy ($n = 5$) produced significantly less amount of IL-5 (36.7 ± 49.4 vs. 433.6 ± 581.2 pg/mL, $P = 0.020$). On the other hand, Cry j 1-induced changes in BTLA ($-1.42 \pm 0.80\%$ vs. $-3.42 \pm 0.97\%$, $P = 0.178$), PD-1 ($0.27 \pm 0.38\%$ vs. $0.73 \pm 0.33\%$, $P = 0.390$) and B7-H1 ($0.10 \pm 0.24\%$ vs. $0.01 \pm 0.34\%$, $P = 0.125$) expression as well as Cry j 1-induced IL-10 (2.4 ± 1.5 vs. 0.2 ± 0.2 pg/mL, $P = 0.137$) and TGF- β (0 ± 0 vs. 0 ± 0 pg/mL) production was not statistically different between the groups. These results suggest that period after reaching of maintenance dose is one of the factors regulating BTLA expression. In addition, the direct effect of SIT on expression of co-inhibitory molecules after reaching the maintenance dose, before the pollen season should be determined.

In conclusion, the present study shows an increase in BTLA-bearing CD4⁺ T cells in patients treated with SIT. Furthermore, the alterations in BTLA expression were associated with allergen-specific IL-5 production. These results suggest that protection of BTLA down-regulation is a key mechanism of SIT. T cell co-signalling molecules are potential targets in the treatment of allergic airway disease [31]. The present study adds support to this and further suggests that regulation of BTLA expression may be of therapeutic benefit in the treatment of allergic airway disease.

Acknowledgements

There are no conflicts of interests. The authors would like to thank Miki Yamamoto, Rie Nomiya and Hisashi Hattori for their excellent technical assistance, and Yuko Okano for her editorial assistance. This work was supported in part by grants from Research on Allergic disease and Immunology of the Ministry of Health, Labor and Welfare, Japan (14210301).

References

- 1 Kowalski ML. Systemic and specific treatment for a global disease: allergen immunotherapy revised. *Allergy* 2006; 61:791–5.
- 2 Purello-D'Ambrosio F, Gangemi S, Merendino RA *et al.* Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. *Clin Exp Allergy* 2001; 31:1295–302.
- 3 Durham SR, Walker SM, Varga E-M *et al.* Long-term clinical efficacy of grass-pollen immunotherapy. *N Engl J Med* 1999; 341:468–75.
- 4 Golden BK, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. *N Engl J Med* 2004; 351:668–74.
- 5 Jutel M, Akdis M, Blaser K, Akdis CA. Mechanisms of allergen specific immunotherapy – T cell tolerance and more. *Allergy* 2006; 61:796–807.
- 6 Kakinoki Y, Ohashi Y, Nakai Y, Tanaka A, Washio Y. Pollen immunotherapy inhibits T helper 1 and 2 cell responses, but suppression of T helper 2 cell response is a more important mechanism related to the clinical efficacy. *Arch Otolaryngol Head Neck Surg* 2000; 126:63–70.
- 7 Gabrielsson S, Soderlund A, Paulie S, van der Pouw Kraan TC, Troye-Blomberg M, Rak S. Specific immunotherapy prevents increased levels of allergen-specific IL-4- and IL-13-producing cells during pollen season. *Allergy* 2001; 56:293–300.
- 8 Wilson DR, Nouri-Aria KT, Walker SM *et al.* Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. *J Allergy Clin Immunol* 2001; 107:971–6.
- 9 Gardner LM, Spyroglou L, O'Hehir RE, Rolland JM. Increased allergen concentration enhances IFN- γ production by allergic donor T cells expressing a peripheral tissue trafficking phenotype. *Allergy* 2004; 59:1308–17.
- 10 Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. *J Allergy Clin Immunol* 2003; 111:1255–61.
- 11 Schwartz RH. A cell culture model for T lymphocyte clonal anergy. *Science* 1990; 248:1349–56.
- 12 Greenwald RJ, Freeman GJ, Sharpe AH. B7 family revised. *Annu Rev Immunol* 2005; 23:515–48.
- 13 Nakada M, Nishizaki K, Yoshino T, Okano M, Masuda Y, Ohta N. CD86 (B7-2) antigen on B cells from atopic patients shows selective, antigen-specific upregulation. *Allergy* 1998; 53:527–31.
- 14 Hattori H, Okano M, Yoshino T *et al.* Expression of costimulatory CD80/CD86-CD28/CD152 molecules in nasal mucosa of patients with perennial allergic rhinitis. *Clin Exp Allergy* 2001; 31:1242–9.
- 15 Okano M, Azuma M, Yoshino T *et al.* Differential role of CD80 and CD86 molecules in the induction and the effector phases of allergic rhinitis in mice. *Am J Respir Crit Care Med* 2001; 164:1501–7.
- 16 Sperling AI, Bluestone JA. ICOS costimulation: it's not just for TH2 cells anymore. *Nat Immunol* 2001; 2:573–4.
- 17 Watanabe N, Gavrieli M, Sedy JR *et al.* BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. *Nat Immunol* 2003; 4:670–9.
- 18 Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based

- switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. *J Immunol* 2004; 173:945–54.
- 19 Hirata H, Arima M, Cheng G *et al*. Effects of CD80 and CD86 on cytokine production in patients with wasp-venom allergy who receive venom immunotherapy. *Cytokine* 2003; 24:1–6.
 - 20 Okano M, Kino K, Takishita T *et al*. Roles of carbohydrates on Cry j1, the major allergen of Japanese cedar pollen, in specific T cell responses. *J Allergy Clin Immunol* 2001; 108:101–8.
 - 21 Youngnak P, Kozono Y, Kozono H *et al*. Differential binding properties of B7-H1 and B7-DC to programmed death-1. *Biochem Biophys Res Commun* 2003; 307:672–7.
 - 22 Otsuki N, Kamimura Y, Hashiguchi M, Azuma M. Expression and function of the B and T lymphocyte attenuator (BTLA/CD272) on human T cells. *Biochem Biophys Res Commun* 2006; 344:1121–7.
 - 23 Okuda M, Ohkubo K, Goto M *et al*. Comparative study of two Japanese rhinoconjunctivitis quality-of-life questionnaires. *Acta Otolaryngol* 2005; 125:736–44.
 - 24 Takahashi K, Takata M, Suwaki T *et al*. New flow cytometric method for surface phenotyping basophils from peripheral blood. *J Immunol Methods* 1993; 162:17–21.
 - 25 Han P, Goularte OD, Rufner K, Wilkinson B, Kaye J. An inhibitory Ig superfamily protein expressed by lymphocytes and APC is also an early marker of thymocyte positive selection. *J Immunol* 2004; 172:5931–9.
 - 26 Wang WF, Chen YJ, Wang Q *et al*. Distinct expression and inhibitory function of B and T lymphocyte attenuator on human T cells. *Tissue Antigens* 2006; 69:145–53.
 - 27 Sone T, Morikubo K, Miyahara M *et al*. T cell epitopes in Japanese cedar (*Cryptomeria japonica*) pollen allergens: choice of major T cell epitopes of Cry j 1 and Cry j 2 toward design of the peptide-based immunotherapeutics for the management of Japanese cedar pollinosis. *J Immunol* 1998; 161:448–57.
 - 28 Hurchla MA, Sedy JR, Garvielli M, Drake CG, Murphy TL, Murphy KM. B and T lymphocytes attenuator exhibits structural and expression polymorphism and is highly induced in anergic CD4+ T cells. *J Immunol* 2005; 174:2277–85.
 - 29 Lin SC, Kou CC, Chan CH. Association of a BTLA gene polymorphism with the risk of rheumatoid arthritis. *J Biomed Sci* 2006; 13:853–60.
 - 30 Tsutsumi Y, Jie X, Ihara K *et al*. Phenotypic and genetic analyses of T-cell-mediated immunoregulation in patients with Type 1 diabetes. *Diabet Med* 2006; 23:1145–50.
 - 31 Krocze R, Hamelmann E. T-cell costimulatory molecules: optimal targets for the treatment of allergic airway disease with monoclonal antibodies. *J Allergy Clin Immunol* 2005; 116:906–9.